p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients

Paola Ulivi, Wainer Zoli, Daniele Calistri, Francesco Fabbri, Anna Tesei, Marco Rosetti, Marta Mengozzi, Dino Amadori

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Aberrant promoter hypermethylation of several known or putative tumor suppressor genes occurs frequently during the etiopathogenesis of lung cancer and is a promising tool for cancer detection. In the present study, promoter hypermethylation of p16INK4A and CDH13 genes was investigated in tumor tissue and in matched serum from 61 patients with histologically confirmed non-small cell lung cancer. Using a fluorescence-based method of methylation-specific PCR(F-MSP), methylation of p16INK4A and CDH13 was detected in 79% and 66% of tumors, respectively, and was not significantly related to conventional clinicopathological characteristics of patients or tumors. Methylation of both genes was observed in 52% of tumors and of at least one gene in 92% of lesions. In matched serum, hypermethylation of p16 INK4A and CDH13 was observed in 26% and 23% of patients, respectively, but as they were not associated, the methylation of at least one gene was detected in 39% of patients. In conclusion, the frequency of p16 INK4A or CDH13 hypermethylation in patient serum, together with evidence of their early occurrence in lung cancerogenesis and the total lack of methylation in serum from healthy individuals, offer a promising tool for non invasive early detection of lung cancer.

Original languageEnglish
Pages (from-to)611-615
Number of pages5
JournalJournal of Cellular Physiology
Volume206
Issue number3
DOIs
Publication statusPublished - Mar 2006

Fingerprint

Methylation
Non-Small Cell Lung Carcinoma
Tumors
Genes
Cells
Cyclin-Dependent Kinase Inhibitor p16
Serum
Neoplasms
Lung Neoplasms
p16 Genes
Tumor Suppressor Genes
Early Detection of Cancer
Fluorescence
Tissue
Polymerase Chain Reaction
Lung

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology
  • Physiology

Cite this

p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. / Ulivi, Paola; Zoli, Wainer; Calistri, Daniele; Fabbri, Francesco; Tesei, Anna; Rosetti, Marco; Mengozzi, Marta; Amadori, Dino.

In: Journal of Cellular Physiology, Vol. 206, No. 3, 03.2006, p. 611-615.

Research output: Contribution to journalArticle

@article{616e628cdbcc4a4fb57b44274287da21,
title = "p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients",
abstract = "Aberrant promoter hypermethylation of several known or putative tumor suppressor genes occurs frequently during the etiopathogenesis of lung cancer and is a promising tool for cancer detection. In the present study, promoter hypermethylation of p16INK4A and CDH13 genes was investigated in tumor tissue and in matched serum from 61 patients with histologically confirmed non-small cell lung cancer. Using a fluorescence-based method of methylation-specific PCR(F-MSP), methylation of p16INK4A and CDH13 was detected in 79{\%} and 66{\%} of tumors, respectively, and was not significantly related to conventional clinicopathological characteristics of patients or tumors. Methylation of both genes was observed in 52{\%} of tumors and of at least one gene in 92{\%} of lesions. In matched serum, hypermethylation of p16 INK4A and CDH13 was observed in 26{\%} and 23{\%} of patients, respectively, but as they were not associated, the methylation of at least one gene was detected in 39{\%} of patients. In conclusion, the frequency of p16 INK4A or CDH13 hypermethylation in patient serum, together with evidence of their early occurrence in lung cancerogenesis and the total lack of methylation in serum from healthy individuals, offer a promising tool for non invasive early detection of lung cancer.",
author = "Paola Ulivi and Wainer Zoli and Daniele Calistri and Francesco Fabbri and Anna Tesei and Marco Rosetti and Marta Mengozzi and Dino Amadori",
year = "2006",
month = "3",
doi = "10.1002/jcp.20503",
language = "English",
volume = "206",
pages = "611--615",
journal = "Journal of cellular and comparative physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients

AU - Ulivi, Paola

AU - Zoli, Wainer

AU - Calistri, Daniele

AU - Fabbri, Francesco

AU - Tesei, Anna

AU - Rosetti, Marco

AU - Mengozzi, Marta

AU - Amadori, Dino

PY - 2006/3

Y1 - 2006/3

N2 - Aberrant promoter hypermethylation of several known or putative tumor suppressor genes occurs frequently during the etiopathogenesis of lung cancer and is a promising tool for cancer detection. In the present study, promoter hypermethylation of p16INK4A and CDH13 genes was investigated in tumor tissue and in matched serum from 61 patients with histologically confirmed non-small cell lung cancer. Using a fluorescence-based method of methylation-specific PCR(F-MSP), methylation of p16INK4A and CDH13 was detected in 79% and 66% of tumors, respectively, and was not significantly related to conventional clinicopathological characteristics of patients or tumors. Methylation of both genes was observed in 52% of tumors and of at least one gene in 92% of lesions. In matched serum, hypermethylation of p16 INK4A and CDH13 was observed in 26% and 23% of patients, respectively, but as they were not associated, the methylation of at least one gene was detected in 39% of patients. In conclusion, the frequency of p16 INK4A or CDH13 hypermethylation in patient serum, together with evidence of their early occurrence in lung cancerogenesis and the total lack of methylation in serum from healthy individuals, offer a promising tool for non invasive early detection of lung cancer.

AB - Aberrant promoter hypermethylation of several known or putative tumor suppressor genes occurs frequently during the etiopathogenesis of lung cancer and is a promising tool for cancer detection. In the present study, promoter hypermethylation of p16INK4A and CDH13 genes was investigated in tumor tissue and in matched serum from 61 patients with histologically confirmed non-small cell lung cancer. Using a fluorescence-based method of methylation-specific PCR(F-MSP), methylation of p16INK4A and CDH13 was detected in 79% and 66% of tumors, respectively, and was not significantly related to conventional clinicopathological characteristics of patients or tumors. Methylation of both genes was observed in 52% of tumors and of at least one gene in 92% of lesions. In matched serum, hypermethylation of p16 INK4A and CDH13 was observed in 26% and 23% of patients, respectively, but as they were not associated, the methylation of at least one gene was detected in 39% of patients. In conclusion, the frequency of p16 INK4A or CDH13 hypermethylation in patient serum, together with evidence of their early occurrence in lung cancerogenesis and the total lack of methylation in serum from healthy individuals, offer a promising tool for non invasive early detection of lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=31944448123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31944448123&partnerID=8YFLogxK

U2 - 10.1002/jcp.20503

DO - 10.1002/jcp.20503

M3 - Article

VL - 206

SP - 611

EP - 615

JO - Journal of cellular and comparative physiology

JF - Journal of cellular and comparative physiology

SN - 0021-9541

IS - 3

ER -